ATE427488T1 - Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion - Google Patents

Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion

Info

Publication number
ATE427488T1
ATE427488T1 AT96921473T AT96921473T ATE427488T1 AT E427488 T1 ATE427488 T1 AT E427488T1 AT 96921473 T AT96921473 T AT 96921473T AT 96921473 T AT96921473 T AT 96921473T AT E427488 T1 ATE427488 T1 AT E427488T1
Authority
AT
Austria
Prior art keywords
cell
hiv
fusion
tropic
isolate
Prior art date
Application number
AT96921473T
Other languages
English (en)
Inventor
Graham Allaway
Virginia Litwin
Paul Maddon
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Application granted granted Critical
Publication of ATE427488T1 publication Critical patent/ATE427488T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96921473T 1995-06-07 1996-06-07 Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion ATE427488T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47551595A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE427488T1 true ATE427488T1 (de) 2009-04-15

Family

ID=23887897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921473T ATE427488T1 (de) 1995-06-07 1996-06-07 Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion

Country Status (8)

Country Link
US (6) US6261763B1 (de)
EP (1) EP0847452B1 (de)
AT (1) ATE427488T1 (de)
AU (1) AU723158B2 (de)
CA (1) CA2224003C (de)
DE (1) DE69637890D1 (de)
ES (1) ES2325042T3 (de)
WO (1) WO1996041020A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041020A1 (en) * 1995-06-07 1996-12-19 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) * 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US6107019A (en) * 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US20040086528A1 (en) * 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
EP0956044A4 (de) * 1996-06-14 2005-01-05 Progenics Pharm Inc Verwendungen eines chemokin-rezeptors zur inhibierung einer hiv-1 infektion
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
CA2342675A1 (en) * 2001-04-02 2002-10-02 Abdelkrim Habi Halogenated rhodamine derivatives and applications thereof
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP1910573B1 (de) 2005-07-22 2013-09-04 CytoDyn, Inc. Verfahren zur reduzierung der viruslast in mit hiv-1 infizierten patienten
WO2009014638A2 (en) * 2007-07-19 2009-01-29 Progenics Pharmaceuticals, Inc. Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US10085783B2 (en) 2013-03-14 2018-10-02 Izi Medical Products, Llc Devices and methods for treating bone tissue
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US10684272B2 (en) 2015-07-15 2020-06-16 Agency For Science, Technology And Research Modulation of hepatitis B virus replication

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI71011C (fi) 1982-02-26 1986-10-27 Ikaplast Automatiskt handeldvapen
FI71010C (fi) 1982-02-26 1986-10-27 Ikaplast Faestanordning foer faestande av en pipa i ett vapens ram
US4886743A (en) 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5126433A (en) 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5854400A (en) 1987-05-29 1998-12-29 Tanox, Inc. Monoclonal antibodies which neutralize HIV-1 infection
US5215913A (en) 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
US5071964A (en) 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US5668149A (en) 1990-01-26 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of human immunodeficiency virus-1 infectivity in human cells
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5817767A (en) 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
US5449608A (en) 1993-03-22 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Parvovirus B19 receptor and parvovirus B19 detection
US5603933A (en) 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
WO1995016789A1 (en) * 1993-12-17 1995-06-22 Progenics Pharmaceuticals, Inc. Methods for using resonance energy transfer-based assay of hiv-1 envelope clycoprotein-mediated membrane fusion, and kits for practicing same
US5504003A (en) 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
EP1148127A3 (de) 1995-06-06 2003-12-03 Human Genome Sciences, Inc. Menschlicher G-Protein ChemokinRezeptor HDGNR10 (CCR5 Rezeptor). Seine verwendungen
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US20040151719A1 (en) 1995-06-06 2004-08-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
MX9709849A (es) 1995-06-06 1998-03-29 Human Genome Sciences Inc Receptor de quimiocina de la proteina g humana o hdgnr10.
JPH10510719A (ja) 1995-06-06 1998-10-20 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒトｇタンパク質ケモカインレセプターｈｄｇｎｒ１０
WO1996041020A1 (en) 1995-06-07 1996-12-19 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
AU1750497A (en) 1996-01-17 1997-08-11 Progenics Pharmaceuticals, Inc. Compounds capable of inhibiting hiv-1 infection
ATE428785T1 (de) 1996-03-01 2009-05-15 Euroscreen Sa Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
US6344545B1 (en) 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US6107019A (en) 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
US5939320A (en) 1996-05-20 1999-08-17 New York University G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
EP0956044A4 (de) 1996-06-14 2005-01-05 Progenics Pharm Inc Verwendungen eines chemokin-rezeptors zur inhibierung einer hiv-1 infektion
US20040086528A1 (en) 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
US5994515A (en) 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
AU3505397A (en) 1996-06-25 1998-01-14 Trustees Of The University Of Pennsylvania, The Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US6100087A (en) 1998-03-11 2000-08-08 City Of Hope Ribozymes targeted to human CCR5 mRNA
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20040228869A1 (en) 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
MXPA01006097A (es) 1998-12-16 2002-04-15 Progenics Pharm Inc Inhibicion sinergistica de la fusion y union de vih-1, composiciones y anticuerpos en la misma.
US6488375B2 (en) * 1999-10-28 2002-12-03 Ocular Sciences, Inc. Tinted contact lens and method for making same
US6692745B2 (en) 2000-01-28 2004-02-17 Arogenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
JP2003523744A (ja) 2000-02-09 2003-08-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｃｃｒ５に対する抗体
WO2001064710A2 (en) 2000-02-29 2001-09-07 Progenics Pharmaceuticals, Inc. Sulfated ccr5 peptides for hiv-1 infection
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
AU2002255642A1 (en) 2001-02-28 2002-09-12 Aaron Diamond Aids Research Centre Sulfated ccr5 peptides for hiv-1 infection
US20030003440A1 (en) 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
US20020146415A1 (en) 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
WO2002085365A1 (en) 2001-04-19 2002-10-31 Bristol-Myers Squibb Company Tricyclic compounds useful as hiv reverse transcriptase inhibitors
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
RU2353357C2 (ru) 2003-05-16 2009-04-27 Юниверсити Оф Мэрилэнд Байотекнолоджи Инститьют Композиции для супрессии экспрессии ccr5 и способы их применения
US20050131042A1 (en) 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
EP1910573B1 (de) 2005-07-22 2013-09-04 CytoDyn, Inc. Verfahren zur reduzierung der viruslast in mit hiv-1 infizierten patienten

Also Published As

Publication number Publication date
DE69637890D1 (de) 2009-05-14
US20030044770A1 (en) 2003-03-06
US20020045161A1 (en) 2002-04-18
EP0847452A4 (de) 2000-04-12
US7901685B2 (en) 2011-03-08
CA2224003A1 (en) 1996-12-19
CA2224003C (en) 2010-04-13
EP0847452B1 (de) 2009-04-01
ES2325042T3 (es) 2009-08-24
EP0847452A1 (de) 1998-06-17
US20090155774A1 (en) 2009-06-18
US7862994B2 (en) 2011-01-04
AU6269096A (en) 1996-12-30
US6972126B2 (en) 2005-12-06
US20060140977A1 (en) 2006-06-29
AU723158B2 (en) 2000-08-17
WO1996041020A1 (en) 1996-12-19
US20070048820A1 (en) 2007-03-01
US6261763B1 (en) 2001-07-17

Similar Documents

Publication Publication Date Title
DE69637890D1 (de) Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
EP0675904A4 (de) Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch.
EA200200503A1 (ru) Способ лечения ревматоидного артрита
NO970221L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
DE69435126D1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE3070803D1 (en) Monoclonal-antibody-producing hybrid cell line, antibody and method of preparing it, therapeutic composition containing it and its diagnostic and therapeutic uses
ATE335072T1 (de) Methoden für inhibition der cd14-abhängigen zellaktivierung
ATE226641T1 (de) Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
AU5055593A (en) Antibodies specific for HIV
SE9301270D0 (sv) Biosensor
DE69608804D1 (de) Di- und trivalente kleine moleküle als selektininhibitoren
FI964845A0 (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
DK407987A (da) Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer
BR0015872A (pt) Agentes antitrombóticos
GB9319877D0 (en) Novel hybridoma & monoclonal antibodies produced thereby
ES2195033T3 (es) Iso-indolonas condensadas utilizadas como inhibidores de proteina quinasa c.
ES2189802T3 (es) Anticuerpos monoclonales contra ck-mb.
ATE274920T1 (de) Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
NO981051L (no) Peptidderivater
ATE132502T1 (de) Peptide, die epitope auf r-ifn-beta repräsentieren, antikörper dagegen, und ihre anwendung
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties